Pharming Group NV:
RUCONEST (rhC1INH) marketed to treat acute Hereditary Angioedema (HAE) attacks with 100% response rate, no relapse, side effects, or plasma risk. Submitted sBLA to FDA for prophylaxis of HAE (recent CRL requesting additional trial). Cash flow positive. Recently announced positive results from a ph2 study of RUCONEST in Contract-induced Nephropathy for patients receiving elective coronary angiography with or without a percutaneous coronary intervention (PCI). Recently filed for approval to begin the first clinical study of RUCONEST in pre-eclampsia, and pursuing additional indications in cardiac protection. Development programs in Pompe and Fabry diseases, Haemophillia.
Leiden, 2333 CR
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by